ADAM10 and lymphoma: ADAM10 sheddase activity carried by these vesicles to bystander lymphoma or stromal cells induces the shedding of TNFα and CD30, with consequent reduction of anti-lymphoma effects exerted by the antibody-drug conjugate brentuximab-Vedotin; this effect is recovered when ExoV contain ADAM10 inhibitors that neutralize the sheddase activity [105].